Desperate families get early access to experimental brain disease drug
NCT ID NCT06594016
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 23 times
Summary
This program offers early access to the investigational drug fosigotifator for people with vanishing white matter or Cree leukoencephalopathy, rare and serious brain diseases. It is not a clinical trial but a way for eligible patients to receive the drug before it is officially approved. A doctor must decide if the potential benefits outweigh the risks for each individual.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VANISHING WHITE MATTER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.